These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 25180841)

  • 1. Health technology assessment in the HIV setting: the case of monotherapy.
    Restelli U; Croce D; Porazzi E; Scolari F; Bonfanti M; Galli M; Gianotti N; Rizzardini G; Garagiola E; Vanzago A; Foglia E
    New Microbiol; 2014 Jul; 37(3):247-61. PubMed ID: 25180841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start.
    Angeletti C; Pezzotti P; Antinori A; Mammone A; Navarra A; Orchi N; Lorenzini P; Mecozzi A; Ammassari A; Murachelli S; Ippolito G; Girardi E
    HIV Med; 2014 Mar; 15(3):165-74. PubMed ID: 24495188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting HIV care costs using CD4 counts from clinical trials.
    Hill A; Gebo K
    Am J Manag Care; 2007 Sep; 13(9):524-8. PubMed ID: 17803366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Identification of patients in antiretroviral treatment as candidates for protease inhibitor monotherapy].
    González-Valdivieso J; Perez Reche C; Gonzalez-Navarro M; Roure Nuez C
    Farm Hosp; 2012; 36(2):111-2. PubMed ID: 22024012
    [No Abstract]   [Full Text] [Related]  

  • 5. New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy).
    Restelli U; Scolari F; Bonfanti P; Croce D; Rizzardini G
    BMC Infect Dis; 2015 Aug; 15():323. PubMed ID: 26259842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial.
    Oddershede L; Walker S; Stöhr W; Dunn DT; Arenas-Pinto A; Paton NI; Sculpher M;
    Pharmacoeconomics; 2016 Aug; 34(8):795-804. PubMed ID: 26966125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART.
    Stoll M; Claes C; Schulte E; Graf von der Schulenburg JM; Schmidt RE
    Eur J Med Res; 2002 Nov; 7(11):463-71. PubMed ID: 12568973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
    Rothbard AB; Lee S; Blank MB
    J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain].
    Smets E; Brogan AJ; Hill A; Adriaenssen I; Sawyer AW; Domingo-Pedrol P; Gostkorzewicz J; Ledesma F
    Enferm Infecc Microbiol Clin; 2013; 31(7):430-6. PubMed ID: 23260386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplification of antiretroviral therapy: a good choice for our patients and the sustainability of our health care system.
    González Rivas L; Sánchez Gómez E; Sánchez del Moral R; Grutzmancher Saiz S; Pujol de la Llave E; Bocanegra Martín C
    Farm Hosp; 2011; 35(6):317-21. PubMed ID: 22019116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric HIV costs across three treatment eras from 1986 to 2007.
    Wilson LS; Basu R; Christenson M; Hensic L; Paoli C; Wara D; Moskowitz JT
    Pediatrics; 2010 Sep; 126(3):e541-9. PubMed ID: 20696721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic impact of delaying or preventing AIDS in persons with HIV.
    Pinkerton SD; Holtgrave DR
    Am J Manag Care; 1999 Mar; 5(3):289-98. PubMed ID: 10351025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessing the direct cost of medical care for HIV between the third and tenth year of ARV treatment in Dakar].
    Boufkhed S; Taverne B
    Bull Soc Pathol Exot; 2014 Oct; 107(4):292-8. PubMed ID: 25048463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
    Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
    HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain.
    Pasquau J; Gostkorzewicz J; Ledesma F; Anceau A; Hill A; Moecklinghoff C
    Appl Health Econ Health Policy; 2012 Mar; 10(2):139-41. PubMed ID: 22293019
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.